News
Zacks Investment Research on MSN16h
Novavax to Report First-Quarter Earnings: Is a Beat in Store?We expect Novavax NVAX to surpass expectations when it reports first-quarter 2025 earnings on May 8, before the opening bell.
Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.
Novavax, Inc. (Nasdaq: NVAX) has updated the terms of the previously announced collaboration and licensing agreement (CLA) ...
Zacks Investment Research on MSN12d
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should KnowNovavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
Novavax (NASDAQ:NVAX) has updated the terms of the previously announced collaboration and licensing agreement with Takeda (TAK).
The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine ...
Zacks.com on MSN11d
Novavax (NVAX) Surges 19.5%: Is This an Indication of Further Gains?Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...
Novavax, Inc. (NVAX) said it has updated the terms of the collaboration and licensing agreement with Takeda. The company noted that the improved financial terms of the amended ...
Shares of Novavax Inc. NVAX slipped 3.90% to $6.41 Thursday, on what proved to be an all-around great trading session for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback